. Cyclic chemotherapy in acute lymphoblastic leukaemia: 5-year survivals. Of 31 children with acute lymphoblastic leukaemia treated with a cyclical scheme of chemotherapy, 19% survived for over 5 years, 16% remained in continuing haematological remission for 5 years, and 13% remained leukaemia free for 5 years. These findings are relevant to potential cure, unlike the median remission duration, which is a measure of palliation.
Between 1964 and 1967, 31 children with acute lymphoblastic leukaemia (ALL) were treated according to the drug schedule shown in Fig. 1A . 6-Mercaptopurine, methotrexate, and cyclophosphamide were given in cyclical rotation at conventional doses for maintenance of remission. The median length of first remission was 13 months (Willoughby and Laurie, 1968) . Whereas the median length of first remission is a valid measurement of palliative therapy, it is the percentage surviving and in remission at 5 years or more that is relevant to cure.
It is now possible to see the long-term results of this therapy, since the last patient was placed upon the schedule over 5 years ago. These results are of interest (1) because they show a marked increase in 5-year survival over that of the preceding chemotherapeutic era, and (2) because they provide a yardstick against which recent and future more complex schedules can be compared in terms of 5-year results.
Clinical materials and methods These were as described earlier (Willoughby and Laurie, 1968) . The drug therapy was as shown in trexate; (b) 6-monthly vincristine plus prednisolone 'pseudoreinduction' courses were superimposed upon the cyclic schedule. These changes are shown in Fig. lB . A marrow examination was performed on the first day of each pseudoreinduction course. Assessment of PAS-positivity of the blast cells in the marrow at diagnosis was performed as described by Laurie (1968) .
Results
All 31 patients with ALL who were placed on this schedule achieved complete remission and there were, therefore, no exclusions on grounds of early death or failure to attain remission. Fig. 2 Group B, 1963; Zuelzer, 1964 Pinkel (1971) , where multiple antileukaemic drugs have been used in remission, either cyclically or in combination, and where higher rates of 5-year survival and 5-year remission have been obtained (Table II) . The best 5-year results are those of Pinkel (1971) with 170% in complete remission and 19% surviving, while a 5-year survival rate of approximately 16% has been reported from Acute Leukemia Group B (Holland, 1971) . The results obtained with the cyclical therapy schedule shown in Fig. IA and B are closely comparable with the more recent American series, and very different from those of the previous chemotherapeutic era either in the U.K. (Till and Hardisty, 1972) or elsewhere (Burchenal, 1968) . In its simplest form the superior long-term results and possible cure are perhaps due to the use of multiple antileukaemic drugs during the period of continuing remission. Appreciation of the likelihood that 1 in 5 patients will survive 5 years and that 1 in 6 may be cured should encourage maximum effort to achieve safe passage through the hazardous first weeks of remission induction therapy and to ensure that arrangements are made for optimum subsequent therapy. There was less force to this argument when fewer than 1 % survived 5 years. Two more recent American series, employing CNS prophylaxis and multiple-drug maintenance therapy, but for which 5-year results are not yet available, appear to be achieving even superior results which, by extrapolation, are likely to give 5-year remission rates in the region of 40% (Fig. 4) 
